Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MMR-varicella zoster virus vaccine - GlaxoSmithKline

Next Previous
Drug Profile

MMR-varicella zoster virus vaccine - GlaxoSmithKline

Alternative Names: GSK-208136; MMRVNS; Priorix-Tetra; PriorixTetra

Latest Information Update: 10 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK
  • Class Measles vaccines; Mumps vaccines; Rubella vaccines; Varicella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Mumps; Rubella; Varicella zoster virus infections

Most Recent Events

  • 03 Aug 2026 GlaxoSmithKline plans a phase IIIa trial for Measles, Mumps, Rubella, Varicella zoster virus infections (Prevention, In children, Combination therapy) in USA, Argentina, Finland, Italy, Puerto Rico, Taiwan, (SC) (NCT07742644)
  • 06 Oct 2016 No development reported - Phase-III for Measles (Prevention) in South Korea (SC)
  • 06 Oct 2016 No development reported - Phase-III for Mumps (Prevention) in South Korea (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top